Search for a trial

A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson*s disease experiencing motor fluctuations (BouNDless)

Primary ObjectiveThe primary objective of the study is to determine the effect of ND0612 on daily *ON* time without troublesome dyskinesia (defined as the sum of "ON" time without dyskinesia and *ON* time with non-troublesome dyskinesia)…

Treating big problems arising from the little brain: A double-blind, sham-controlled, exploratory trial to investigate the effect of cerebellar anodal transcranial direct current stimulation in patient with CCAS

The primary objective is:To investigate whether a two-weeks intervention with cerebellar anodal tDCS could improve CCAS severity in patients with cerebellar disorders compared to sham stimulation.Secondary objectives are:• To investigate whether a…

The Dutch Parkinson GBA Ambroxol trial (DUPARG-AMBROXOL):
A randomised, double-blind, placebo-controlled, single-center trial with Ambroxol in Parkinson patients with a GBA mutation

The primary objective is to compare the effectiveness of ambroxol versus placebo on the MDS-UPDRS part III motor sub-score in the *practically defined OFF-medication state* in patients with moderate PD, carrying a GBA mutation. The hypothesis is…

A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson*s Disease

The main objective of PD0053 is to provide POC for the efficacy of the ASYN misfolding inhibitor UCB0599 in reducing disease progression in study participants with early-stage PD, and to instruct later stage development. The ultimate goal is to…

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled
Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson*s Disease

This study has been transitioned to CTIS with ID 2023-505645-12-00 check the CTIS register for the current data. Main objective: To evaluate the efficacy of BIIB122 225 mg compared with placebo.Secondary objective: To evaluate the efficacy, safety…

The effect of mindfulness-based cognitive therapy on psychological distress in people with Parkinson*s Disease: clinical effects and cerebral mechanisms.

Test whether a mindfulness-based cognitive therapy intervention (MBCT) improves psychological distress, clinical symptoms, slows neurodegeneration, and/or enhances neuroplasticity in PD.

Transcranial Alternating Current Stimulation (tACS) as a novel treatment option: a proof of concept study in Adult Classic Galactosemia

Main objective: We propose a proof of concept study to apply noninvasive brain stimulation, specifically tACS, for the first time to adult CG patients with the aim to find stimulation protocols that improve their motor and language performance by…

Conservative iron chelation as a disease-modifying strategy in Parkinson*s disease

Objectives The main objective of the FAIR-PARK II trial is to demonstrate an effect of DFP on the course of PD (including both disease-modifying and symptomatic effects). The trial's overall objective can be summarized as follows: to…

Lower urinary tract symptoms in Parkinson's disease effectiveness of pelvic floor muscle exercises and electrical stimulation

Objective: To study the effectiveness of pelvic physical therapy and ES in patients with PD suffering from LUTS. Which are the most effective parameters for ES. Intervention: Intervention: 8 treatment sessions of 30 minutes pelvic physical therapy…

Randomized Controlled Trial comparing imaging-based programming with threshold-assessment based programming of Deep Brain Stimulation in Parkinson's Disease.

The aim of this study is to assess whether the effectiveness of STN DBS for the treatment of Parkinson motor symptoms using imaging-based DBS programming is non-inferior compared to DBS programming with the current standard practice of clinical…

A randomized phase 1b/2a trial of the effectiveness of intermittent hypoxia interventions in Parkinson*s disease

To explore the safety, feasibility and net symptomatic effects of multiple intermittent hypoxia intervention sessions in individuals with PD. Secondary outcomes include exploring induction of relevant neuroprotective pathways as measured in serum.

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OF PTC857 IN ADULT SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (CARDINALS)

This study has been transitioned to CTIS with ID 2023-510317-26-00 check the CTIS register for the current data. To evaluate the efficacy of PTC857 in reducing disease progression in subjects with amyotrophic lateral sclerosis (ALS)

The HEADS-Up Trial: Sleeping in a head-up tilt position to treat orthostatic hypotension, supine hypertension and nocturia in Parkinson's disease

To assess the efficacy and tolerability of HUTS with different angles, leading to optimal implementation strategies of HUTS to alleviate the impact of orthostatic hypotension and supine hypertension in PD

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active
Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.

Main objective:To demonstrate superior efficacy with evobrutinib compared to Teriflunomide in terms of Annualized Relapse Rate (ARR) Secondary objectives:a.To demonstrate the efficacy of evobrutinib relative to that of Teriflunomide on disability…

A randomised, placebo-controlled, multicentre phase IIb study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinson*s disease

Primary:To evaluate the effects of pirepemat on falls frequency as compared to placebo.Secundary:To evaluate the effects of pirepemat on Parkinson's disease motor symptoms as compared to placebo.To evaluate the effects of pirepemat on apathy as…

Levodopa in early Parkinson*s disease;LEAP-5Y-study:
Follow-up of the Levodopa in early Parkinson's disease study

To investigate whether early treatment with levodopa has a delayed beneficial effect on PD symptoms and functional health, and improves the ability to (maintain) work, reduces the use of (informal) care, caregiver burden, and costs. Additionally,…

Slow-SPEED-NL: Slowing Parkinson's Early through Exercise Dosage-Netherlands

The primary objective is to determine the feasibility of a remote intervention study to promote physical activity in people with iRBD. The secondary objectives are to determine the longitudinal effect of an exercise intervention in people with iRBD…

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE

The primary efficacy objective for this study is to evaluate the efficacy of RO7234292 compared with placebo.The secondary efficacy objective for this study is to evaluate the efficacy of RO7234292 compared with placebo.The safety objective for this…

A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants with Parkinson*s Disease

Primary Objectives: 1. To evaluate the safety and tolerability of UB-312. 2. To evaluate the immunogenicity of UB-312 as determined by anti-alpha-synuclein (anti-aSyn) antibodies in blood and cerebrospinal fluid (CSF).

Randomized, double-blind, placebo-controlled, multiple dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of YTX-7739, a novel oral inhibitor of Stearoyl-CoA-desaturases, in healthy volunteers and patients with Parkinson*s disease

To investigate the safety, tolerability and pharmacokinetics after multiple daily doses of YTX-7739